Recent Advances of Drug Design Strategies for Classical KRAS Mutations
DOI:
https://doi.org/10.62051/yc6p5d86Keywords:
KRAS, mutation, drug design strategies.Abstract
KRAS, one of the most common oncogenic mutations, is considered to be a potential target for design of cancer therapies. Previous studies have suggested a poor therapeutic index and lack of efficacy of drugs targeting the KRAS signalling pathway and even leading to think “undrugged”. But recently, major breakthrough in KRAS was achieved in a decade and even up to hit the market which really inspired a lot. This review aims to illustrate the recent advances of drug design strategies for different types of KRAS mutations, including small molecular inhibitors, PROTAC and others.
Downloads
References
[1] Martinez P et al 2016 Nat. Commun. 7 12158.
[2] Santos E and Nebreda A R 1989 Faseb J. 3 2151-63
[3] Vetter I R and Wittinghofer A 2001 Science 294 1299-304.
[4] Carvalho Dias P et al 2018 Cancer Res. 78 7-14
[5] Hobbs G A, Der C J and Rossman K L 2016 J. Cell Sci. 129 1287-92
[6] Xie X et al 2023 Signal Transduction and Targeted Therapy 8 335
[7] Huang L et al 2021 Signal Transduction and Targeted Therapy 6 386
[8] FDA Approves First KRAS Inhibitor: Sotorasib 2021Cancer Discovery 11 Of4.
[9] Hallin J et al 2020 Cancer Discovery 10 54-71
[10] Salem M E et al 2022 JCO Precis Oncol. 6 e2100245.
[11] Dong X et al 2024 Cancer Research 84 CT119
[12] Singhal A, Li B T and O’Reilly E M 2024 Nature Medicine 30 969-983
[13] Wang X et al 2022 Journal of Medicinal Chemistry 65 3123-3133
[14] Wei D et al 2024 Clin Cancer Res. 30 655-662
[15] Zhou X, Ji Y and Zhou J. 2023 Molecules 28 3615
[16] Nagashima T et al 2022 European Journal of Cancer 174 S30
[17] Tran T H et al 2020 Proceedings of the National Academy of Sciences of the United States of America 117 3363-3364
[18] Escher T and Satchell K 2023 Molecular Therapy 31 1904-1919
[19] Mao Z et al 2022 Cell Discovery 8 5
[20] Hoffmann M et al 2023 Journal of Clinical Oncology 41 2543
[21] Holderfield M et al 2024 Nature 629 919–926
[22] Mark A M et al 2021 New England Journal of Medicine 384 2382-2393
[23] Xue J Y et al 2020 Nature 577 421-425
[24] Dy G K et al 2023 J Clin Oncol. 41 3311-3317
[25] Yang F et al 2022 European Journal of Medicinal Chemistry 230 114088
[26] Toure M and Crews C M 2016 Angew. Chem. Int. Engl. 55 1966-1973
[27] Burslem G M et al 2018 Cell Chem. Biol. 25 67-77
[28] Zeng M et al 2020 Cell Chemical Biology 27 19-31
[29] Bond M J et al 2020 ACS Central Science 6 1367-1375
[30] Tolcher A W et al 2023 Journal of Clinical Oncology 41 TPS764
[31] Lake D 2016 Cell Mol. Life Sci. 73 4397-4413
[32] Smith K et al 2023 Molecular Cancer Research 21 PR09
[33] Punekar S R et al 2022 Nature Reviews Clinical Oncology 19 637-655
[34] Watanabe T et al 2011 Dis. Colon. Rectum. 54 1170-8
[35] Lee W et al 2018 Scientific Reports 8 11879
[36] Kim W et al 2018 Genome Res. 28 374-82
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
